ONO 4819

Drug Profile

ONO 4819

Alternative Names: ONO 4819CD

Latest Information Update: 26 May 2006

Price : $50

At a glance

  • Originator Ono Pharmaceutical
  • Class Heptanoic acids; Osteoporosis therapies
  • Mechanism of Action Dinoprostone agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Fracture

Most Recent Events

  • 31 Mar 2006 Discontinued - Phase-II for Fracture treatment in Japan (Injection)
  • 31 Mar 2002 Phase-II clinical trials in Fracture treatment in Japan (Injection)
  • 14 Nov 2001 Phase-I clinical trials for Fracture treatment in Japan (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top